Comparison of two atracurium dosing regimens in dogs undergoing ophthalmic surgery
Abstract
OBJECTIVE: To compare two atracurium intravenous dosing protocols, intermittent boluses (BOL) and variable rate infusion (VRI), for total dose, neuromuscular blockade depth and recovery, need for reversal, and extubation times in dogs undergoing ophthalmic surgery. MATERIALS AND METHODS: A total of 48 anaesthetic records (24 per group) were retrospectively analysed from dogs meeting predefined inclusion criteria. Extracted data included total atracurium dose, dose rate, train-of-four count (TOFC) and ratio (TOFR), duration within TOFR 0.2-0.7, time to recover 0.9TOFR, extubation time, and reversal requirement. Data were analysed with Welch's t-tests, Wilcoxon rank-sum, or Fisher's exact tests. Effect estimates for reversal requirements were expressed as risk ratios (RRs), risk differences (RDs), odds ratios, and number needed to treat. Significance was set at p < 0.05. RESULTS: ; p = 0.010). Dogs receiving VRI spent longer within a TOFR 0.2-0.7. Time to 0.9TOFR was shorter in VRI compared with BOL (12.5 ± 6.3 versus 41.5 ± 14.4 minutes; p < 0.001), as was extubation time (31.1 ± 29.3 versus 62.0 ± 21.2 minutes; p < 0.001). Neostigmine reversal was required in 2/24 dogs in VRI (8%) and 7/24 dogs in BOL (29%) (p = 0.140), corresponding to a RR of 0.29 (95% confidence interval 0.07-1.24) and a RD of -21% (95% confidence interval -42-0). CONCLUSIONS AND CLINICAL RELEVANCE: Atracurium VRI was associated with lower dose rate, more stable neuromuscular blockade depth, faster recovery, and shorter extubation times than BOL injection. These findings support the potential clinical advantages of VRI in canine ophthalmic anaesthesia.
Fields of Study & Subjects
Anesthesia and Sedative Agents
Anesthesia and Pain Management
Veterinary Pharmacology and Anesthesia
Publication details
- Journal / source
- Veterinary Anaesthesia and Analgesia
- Publisher
- Elsevier BV
- Volume
- 53
- Issue
- 2
- Pages
- 101188–101188
- Publication date
- 20 January 2026
- Language
- EN